Results 101 to 110 of about 4,976 (285)

Extraction of Hidden Authentication Factors from Possessive Information [PDF]

open access: gold, 2023
Nilobon Nanglae   +2 more
openalex   +1 more source

C2α‐carbanion‐protonating glutamate discloses tradeoffs between substrate accommodation and reaction rate in actinobacterial 2‐hydroxyacyl‐CoA lyase

open access: yesFEBS Open Bio, EarlyView.
Enzymes of the 2‐hydroxyacyl‐CoA lyase group catalyze the condensation of formyl‐CoA with aldehydes or ketones. Thus, by structural adaptation of active sites, practically any pharmaceutically and industrially important 2‐hydroxyacid could be biotechnologically synthesized. Combining crystal structure analysis, active site mutations and kinetic assays,
Michael Zahn   +4 more
wiley   +1 more source

Predicting and Comparing the Subjective Health Experience of Older Cancer Survivors and Non‐Cancer Survivors: A Modeling Approach

open access: yesAging and Cancer, EarlyView.
This study underscores the significant influence of frailty and vitality on the subjective health experience of older cancer survivors with acceptance and control emerging as salient mediators. These findings affirm the conceptual and empirical robustness of the model highlighting its potential utility in shaping future interventions for older cancer ...
Damien S. E. Broekharst   +4 more
wiley   +1 more source

The Aging Blood: Cellular Origins, Circulating Drivers, and Therapeutic Potential

open access: yesAging and Cancer, EarlyView.
As a conduit linking all organs, the blood system both reflects and actively drives systemic aging. This review highlights how circulating pro‐aging and antiaging factors and age‐associated hematopoietic stem cell dysfunction contribute to immunosenescence and multi‐organ decline, positioning the hematopoietic system as a target for aging intervention.
Hanqing He, Jianwei Wang
wiley   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy